- Sept 3 (Reuters) - Zymogenetics Inc:
* Zymogenetics and Merck serono restructure partnership
* Says will no longer be responsible for funding development costs
* Says exercised its contractual right to convert to worldwide royalty license
with respect to ongoing development of atacicept
* Says Merck serono will now have exclusive worldwide development and
commercialization rights for atacicept
* Says Merck serono will make milestone payments to Zymogenetics
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
tf.TFN-Europe_newsdesk@thomsonreuters.com wj COPYRIGHT Copyright Thomson Financial News Limited 2008. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
* Zymogenetics and Merck serono restructure partnership
* Says will no longer be responsible for funding development costs
* Says exercised its contractual right to convert to worldwide royalty license
with respect to ongoing development of atacicept
* Says Merck serono will now have exclusive worldwide development and
commercialization rights for atacicept
* Says Merck serono will make milestone payments to Zymogenetics
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780))
tf.TFN-Europe_newsdesk@thomsonreuters.com wj COPYRIGHT Copyright Thomson Financial News Limited 2008. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.